+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Atypical Teratoid Rhabdoid Tumours Treatment Market Report and Forecast 2023-2031

  • PDF Icon

    Report

  • 147 Pages
  • April 2023
  • Region: Global
  • Expert Market Research
  • ID: 5780669
The global atypical teratoid rhabdoid tumours (ATRT) treatment market is expected to grow at a compound annual growth rate (CAGR) of 7.9% from 2023 to 2031. The increasing incidence of ATRT, the development of novel treatments, and the growing demand for targeted therapies are the primary drivers of the market growth.

Atypical Teratoid Rhabdoid Tumours Treatment Market: Introduction

Atypical teratoid rhabdoid tumours (ATRT) are a rare and aggressive type of brain tumour that typically affects children under the age of three. The tumours are characterized by the loss of a tumour suppressor gene called INI1 or SMARCB1, which is responsible for regulating cell growth. ATRT is often difficult to treat and has a poor prognosis, with a five-year survival rate of less than 20%. The market is dominated by chemotherapy, which is the primary treatment for ATRT. The market is also driven by the development of targeted therapies and immunotherapies, which are designed to specifically target the tumour cells and enhance the immune response against cancer.

Atypical Teratoid Rhabdoid Tumours Epidemiology

ATRT is a rare type of cancer, accounting for less than 1% of all paediatric brain tumours. The incidence of ATRT is highest in children under the age of three, with approximately 60% of cases occurring in this age group. ATRT is more common in boys than girls, with a male-to-female ratio of approximately 1.5:1. The exact cause of ATRT is unknown but there are several risk factors that have been identified. These include genetic syndromes such as the rhabdoid tumour predisposition syndrome, exposure to ionizing radiation, and mutations in the INI1 or SMARCB1 gene.

ATRT is a highly aggressive tumour and has a poor prognosis. The five-year survival rate for children with ATRT is less than 20%. However, recent advances in treatment, including the development of targeted therapies and immunotherapies, have improved outcomes for some patients.

Atypical Teratoid Rhabdoid Tumours Treatment Market Segmentations

The market can be categorised into treatment method, route of administration, treatment channel, and region.

Market Breakup by Treatment Method

  • Surgery
  • Chemotherapy
  • Radiation
  • Targeted Immunotherapy
  • Others

Market Breakup by Route of Administration

  • Oral
  • Parenteral
  • Intravitreal
  • Subretinal
  • Topical
  • Molecule Type

Market Breakup by Treatment Channel

  • Public
  • Private

Atypical Teratoid Rhabdoid Tumours Treatment Market Breakup by Region

North America

  • United States of America
  • Canada

Europe

  • United Kingdom
  • Germany
  • France
  • Italy
  • Others

Asia Pacific

  • China
  • Japan
  • India
  • ASEAN
  • Australia
  • Others

Latin America

  • Brazil
  • Argentina
  • Mexico
  • Others

Middle East and Africa

  • Saudi Arabia
  • United Arab Emirates
  • Nigeria
  • South Africa
  • Others

Atypical Teratoid Rhabdoid Tumours Treatment Market Scenario

The market is expected to witness significant growth in the coming years, driven by the increasing incidence of ATRT and the development of novel treatments. The market is highly competitive, with several multinational companies and small and medium-sized enterprises operating in the market.

Chemotherapy is the primary treatment for ATRT and dominates the ATRT treatment market. However, the market is also driven by the development of targeted therapies and immunotherapies, which have shown promising results in clinical trials. The increasing demand for personalized medicine and the growing focus on precision oncology are expected to further drive market growth.

North America dominates the ATRT treatment market, accounting for over 50% of the global market share. The high incidence of ATRT in the region, coupled with the presence of a well-established healthcare infrastructure, is driving market growth. Europe is the second-largest market for ATRT treatment, with the increasing adoption of novel therapies and the growing focus on personalized medicine driving market growth.

The Asia Pacific region is expected to witness the highest growth rate during the forecast period, owing to the increasing incidence of ATRT in the region and the rising healthcare expenditure. The growing awareness about ATRT and the availability of new treatment options are also expected to contribute to market growth.

Key Players in the Global Atypical Teratoid Rhabdoid Tumours Treatment Market

The report gives an in-depth analysis of the key players involved in the atypical teratoid rhabdoid tumours treatment market, sponsors manufacturing the drugs, and putting them through trials to get FDA approvals. The companies included in the market are as follows:
  • Takeda Pharmaceutical Company Limited
  • Vyriad, Inc
  • Novartis AG
  • Pfizer Inc
  • Ipsen Pharma
  • Exelixis, Inc
  • Secura Bio
  • Istari Oncology Inc

Table of Contents

1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage - Key Segmentation and Scope
2 Research Methodology3 Executive Summary
4 Atypical Teratoid Rhabdoid Tumours Overview
4.1 Guidelines and Stages
4.2 Pathophysiology
4.3 Screening and Diagnosis
4.4 Treatment Pathway
5 Patient Profile
5.1 Patient Profile Overview
5.2 Patient Psychology and Emotional Impact Factors
5.3 Risk Assessment and Treatment Success Rate
6 Current Scenario Evaluation and Regulatory Framework
6.1 Emerging Therapies and Clinical Trials
6.2 Patent Landscape
6.2.1 Patent Overview
6.2.1.1 Patent Status and Expiry
6.2.1.2 Timelines from Drug Development to Commercial Launch
6.2.1.3 New Drug Application
6.2.1.3.1 Documentation and Approval Process
6.3 Cost of Treatment
6.4 Regulatory Framework
6.4.1 Regulatory Overview
6.4.1.1 US FDA
6.4.1.2 EU EMA
6.4.1.3 INDIA CDSCO
6.4.1.4 JAPAN PMDA
6.4.1.5 Others
7 Challenges and Unmet Needs
7.1 Treatment Pathway Challenges
7.2 Compliance and Drop-Out Analysis
7.3 Awareness and Prevention Gaps
8 Global Atypical Teratoid Rhabdoid Tumours Treatment Market
8.1 Global Atypical Teratoid Rhabdoid Tumours Treatment Market Overview
8.2 Global Atypical Teratoid Rhabdoid Tumours Treatment Market Analysis
8.2.1 Market Overview
8.2.1.1 Global Atypical Teratoid Rhabdoid Tumours Treatment Market Historical Value (2016-2022)
8.2.1.2 Global Atypical Teratoid Rhabdoid Tumours Treatment Market Forecast Value (2023-2031)
8.2.2 Global Atypical Teratoid Rhabdoid Tumours Treatment Market by Treatment Method
8.2.2.1 Market Overview
8.2.2.1.1 Surgery
8.2.2.1.2 Chemotherapy
8.2.2.1.3 Radiation
8.2.2.1.4 Targeted Immunotherapy
8.2.2.1.5 Others
8.2.3 Global Atypical Teratoid Rhabdoid Tumours Treatment Market by Route of Drug Administration
8.2.3.1 Market Overview
8.2.3.1.1 Oral
8.2.3.1.2 Parenteral
8.2.3.1.3 Intravitreal
8.2.3.1.4 Subretinal
8.2.3.1.5 Topical
8.2.3.1.6 Molecule Type
8.2.3.1.7 Others
8.2.4 Global Atypical Teratoid Rhabdoid Tumours Treatment Market by Distribution Channel
8.2.4.1 Market Overview
8.2.4.1.1 Hospital Pharmacies
8.2.4.1.2 Retail Pharmacies
8.2.4.1.3 Online Pharmacies
8.2.5 Global Atypical Teratoid Rhabdoid Tumours Treatment Market by Region
8.2.5.1 Market Overview
8.2.5.1.1 North America
8.2.5.1.2 Europe
8.2.5.1.3 Asia Pacific
8.2.5.1.4 Latin America
8.2.5.1.5 Middle East and Africa
9 North America Atypical Teratoid Rhabdoid Tumours Treatment Market
9.1 Market Share by Country
9.2 United States of America
9.2.1 Historical Trend (2016-2022)
9.2.2 Forecast Trend (2023-2031)
9.3 Canada
9.3.1 Historical Trend (2016-2022)
9.3.2 Forecast Trend (2023-2031)
10 Europe Atypical Teratoid Rhabdoid Tumours Treatment Market
10.1 Market Share by Country
10.2 United Kingdom
10.2.1 Historical Trend (2016-2022)
10.2.2 Forecast Trend (2023-2031)
10.3 Germany
10.3.1 Historical Trend (2016-2022)
10.3.2 Forecast Trend (2023-2031)
10.4 France
10.4.1 Historical Trend (2016-2022)
10.4.2 Forecast Trend (2023-2031)
10.5 Italy
10.5.1 Historical Trend (2016-2022)
10.5.2 Forecast Trend (2023-2031)
10.6 Others
11 Asia Pacific Atypical Teratoid Rhabdoid Tumours Treatment Market
11.1 Market Share by Country
11.2 China
11.2.1 Historical Trend (2016-2022)
11.2.2 Forecast Trend (2023-2031)
11.3 Japan
11.3.1 Historical Trend (2016-2022)
11.3.2 Forecast Trend (2023-2031)
11.4 India
11.4.1 Historical Trend (2016-2022)
11.4.2 Forecast Trend (2023-2031)
11.5 ASEAN
11.5.1 Historical Trend (2016-2022)
11.5.2 Forecast Trend (2023-2031)
11.6 Australia
11.6.1 Historical Trend (2016-2022)
11.6.2 Forecast Trend (2023-2031)
11.7 Others
12 Latin America Atypical Teratoid Rhabdoid Tumours Treatment Market
12.1 Market Share by Country
12.2 Brazil
12.2.1 Historical Trend (2016-2022)
12.2.2 Forecast Trend (2023-2031)
12.3 Argentina
12.3.1 Historical Trend (2016-2022)
12.3.2 Forecast Trend (2023-2031)
12.4 Mexico
12.4.1 Historical Trend (2016-2022)
12.4.2 Forecast Trend (2023-2031)
12.5 Others
13 Middle East and Africa Atypical Teratoid Rhabdoid Tumours Treatment Market
13.1 Market Share by Country
13.2 Saudi Arabia
13.2.1 Historical Trend (2016-2022)
13.2.2 Forecast Trend (2023-2031)
13.3 United Arab Emirates
13.3.1 Historical Trend (2016-2022)
13.3.2 Forecast Trend (2023-2031)
13.4 Nigeria
13.4.1 Historical Trend (2016-2022)
13.4.2 Forecast Trend (2023-2031)
13.5 South Africa
13.5.1 Historical Trend (2016-2022)
13.5.2 Forecast Trend (2023-2031)
13.6 Others
14 Global Atypical Teratoid Rhabdoid Tumours Treatment Market Dynamics
14.1 Market Drivers and Constraints
14.2 SWOT Analysis
14.3 Porter’s Five Forces Model
14.4 Key Demand Indicators
14.5 Key Price Indicators
14.6 Industry Events, Initiatives, and Trends
14.7 Value Chain Analysis
15 Supplier Landscape
15.1 Takeda Pharmaceutical Company Limited
15.1.1 Company Overview
15.1.2 Product Portfolio
15.1.3 Demographic Reach and Achievements
15.1.4 Mergers and Acquisitions
15.1.5 Certifications
15.2 Vyriad, Inc.
15.2.1 Company Overview
15.2.2 Product Portfolio
15.2.3 Demographic Reach and Achievements
15.2.4 Mergers and Acquisitions
15.2.5 Certifications
15.3 Novartis AG
15.3.1 Company Overview
15.3.2 Product Portfolio
15.3.3 Demographic Reach and Achievements
15.3.4 Mergers and Acquisitions
15.3.5 Certifications
15.4 Pfizer Inc.
15.4.1 Company Overview
15.4.2 Product Portfolio
15.4.3 Demographic Reach and Achievements
15.4.4 Mergers and Acquisitions
15.4.5 Certifications
15.5 Ipsen Pharma
15.5.1 Company Overview
15.5.2 Product Portfolio
15.5.3 Demographic Reach and Achievements
15.5.4 Mergers and Acquisitions
15.5.5 Certifications
15.6 Exelixis, Inc.
15.6.1 Company Overview
15.6.2 Product Portfolio
15.6.3 Demographic Reach and Achievements
15.6.4 Mergers and Acquisitions
15.6.5 Certifications
15.7 Secura Bio
15.7.1 Company Overview
15.7.2 Product Portfolio
15.7.3 Demographic Reach and Achievements
15.7.4 Mergers and Acquisitions
15.7.5 Certifications
15.8 Istari Oncology Inc.
15.8.1 Company Overview
15.8.2 Product Portfolio
15.8.3 Demographic Reach and Achievements
15.8.4 Mergers and Acquisitions
15.8.5 Certifications
16 Global Atypical Teratoid Rhabdoid Tumours Treatment Market- Drug Distribution Model (Additional Insight)
16.1 Overview
16.2 Potential Distributors
16.3 Key Parameters for Distribution Partner Assessment
17 Payment Methods (Additional Insight)
17.1 Government Funded
17.2 Private Insurance
17.3 Out-of-Pocket

Companies Mentioned

  • Takeda Pharmaceutical Company
  • Vyriad Inc.
  • Novartis Oncology
  • Pfizer, Inc.
  • Ipsen Pharma
  • Exelixis, Inc.
  • Secura Bio, Inc.
  • Istari Oncology Inc.

Methodology

Loading
LOADING...